{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tumor+Sample+for+Analysis&page=6", "query": { "intervention": "Tumor Sample for Analysis", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 1203, "total_pages": 121, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tumor+Sample+for+Analysis&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tumor+Sample+for+Analysis&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T09:33:52.601Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01869218", "title": "Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Neoplasms" ], "interventions": [], "intervention_types": [], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2013-04-02", "completion_date": "2021-01-15", "has_results": false, "last_update_posted_date": "2022-02-09", "last_synced_at": "2026-11-15T09:33:52.601Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01869218" }, { "nct_id": "NCT05382338", "title": "A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Medulloblastoma" ], "interventions": [ { "name": "Audiometric Test", "type": "PROCEDURE" }, { "name": "Auditory Brainstem Response", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Sodium Thiosulfate", "type": "DRUG" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "4 Years to 21 Years" }, "enrollment_count": 225, "start_date": "2023-02-20", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-15T09:33:52.601Z", "location_count": 106, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 92 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05382338" }, { "nct_id": "NCT00831844", "title": "Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Rhabdomyosarcoma", "Adult Synovial Sarcoma", "Childhood Hepatoblastoma", "Childhood Synovial Sarcoma", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Adrenocortical Carcinoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Childhood Liver Cancer", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Ewing Sarcoma/Peripheral Primitive", "Neuroectodermal Tumor", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Recurrent Retinoblastoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors" ], "interventions": [ { "name": "cixutumumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "7 Months to 30 Years" }, "enrollment_count": 116, "start_date": "2009-01", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2015-03-30", "last_synced_at": "2026-11-15T09:33:52.601Z", "location_count": 93, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00831844" }, { "nct_id": "NCT05307939", "title": "A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV", "Oropharynx Cancer", "HPV-Related Carcinoma", "HPV-Related Malignancy", "HPV Positive Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "HPV ctDNA Assay", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Studies", "type": "DIAGNOSTIC_TEST" }, { "name": "EORTC QLQ H&N 35 and C30", "type": "BEHAVIORAL" }, { "name": "MDADI-HN", "type": "BEHAVIORAL" }, { "name": "COST-FACIT", "type": "BEHAVIORAL" }, { "name": "Intensity-Modulated Radiation Therapy (Arm A)", "type": "RADIATION" }, { "name": "Chemoradiation (Arm B)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "BEHAVIORAL", "RADIATION", "COMBINATION_PRODUCT" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-03-24", "completion_date": "2027-03-24", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-11-15T09:33:52.601Z", "location_count": 8, "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05307939" }, { "nct_id": "NCT02425800", "title": "Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Benign Prostatic Hyperplasia", "Prostate Carcinoma" ], "interventions": [ { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 43, "start_date": "2015-07-28", "completion_date": "2021-08-03", "has_results": false, "last_update_posted_date": "2021-09-01", "last_synced_at": "2026-11-15T09:33:52.601Z", "location_count": 2, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02425800" }, { "nct_id": "NCT04529044", "title": "177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Recurrent Breast Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68-DOTATATE", "type": "RADIATION" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2026-06-30", "completion_date": "2027-12-20", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-11-15T09:33:52.601Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04529044" }, { "nct_id": "NCT05172245", "title": "Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Head and Neck Carcinoma of Unknown Primary", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Locally Advanced Hypopharyngeal Squamous Cell Carcinoma", "Locally Advanced Laryngeal Squamous Cell Carcinoma", "Locally Advanced Nasal Cavity Squamous Cell Carcinoma", "Locally Advanced Oral Cavity Squamous Cell Carcinoma", "Locally Advanced Oropharyngeal Squamous Cell Carcinoma", "Locally Advanced Paranasal Sinus Squamous Cell Carcinoma", "Locally Advanced Sinonasal Squamous Cell Carcinoma", "Maxillary Sinus Squamous Cell Carcinoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Sinonasal Cancer AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Sinonasal Cancer AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Lip and Oral Cavity Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Sinonasal Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2022-09-19", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T09:33:52.601Z", "location_count": 17, "location_summary": "Tampa, Florida • Chicago, Illinois • Fairway, Kansas + 13 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05172245" }, { "nct_id": "NCT02833506", "title": "Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Cancer", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Cancer", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Recombinant NY-ESO-1 Protein", "type": "BIOLOGICAL" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2017-12-08", "completion_date": "2019-08-15", "has_results": false, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-11-15T09:33:52.601Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02833506" }, { "nct_id": "NCT01748747", "title": "Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Recurrent Melanoma", "Stage IIA Melanoma", "Stage IIB Melanoma", "Stage IIC Melanoma", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "Montanide ISA 51 VG", "type": "DRUG" }, { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "Gag:267-274 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "resiquimod", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2012-10", "completion_date": "2017-03-30", "has_results": false, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-11-15T09:33:52.601Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01748747" }, { "nct_id": "NCT01957709", "title": "Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Myxoid Liposarcoma", "Round Cell Liposarcoma", "Synovial Sarcoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Recombinant Interferon Gamma", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-09-25", "completion_date": "2018-06-01", "has_results": true, "last_update_posted_date": "2019-07-10", "last_synced_at": "2026-11-15T09:33:52.601Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01957709" } ] }